LEADER 03774nam 2200685Ia 450 001 9910782987903321 005 20230721005356.0 010 $a1-4443-6059-0 010 $a1-282-00763-7 010 $a9786612007637 010 $a1-4443-0357-0 010 $a1-4443-0358-9 035 $a(CKB)1000000000722814 035 $a(EBL)416492 035 $a(OCoLC)476248454 035 $a(SSID)ssj0000231079 035 $a(PQKBManifestationID)11187388 035 $a(PQKBTitleCode)TC0000231079 035 $a(PQKBWorkID)10216957 035 $a(PQKB)10180872 035 $a(MiAaPQ)EBC416492 035 $a(Au-PeEL)EBL416492 035 $a(CaPaEBR)ebr10300898 035 $a(CaONFJC)MIL200763 035 $a(EXLCZ)991000000000722814 100 $a20080529d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aQuality in laboratory hemostasis and thrombosis$b[electronic resource] /$fSteve Kitchen, John D. Olson, F. Eric Preston 210 $aChichester, West Sussex ;$aHoboken, NJ $cWiley-Blackwell$d2009 215 $a1 online resource (227 p.) 300 $aDescription based upon print version of record. 311 $a1-4051-6803-X 320 $aIncludes bibliographical references and index. 327 $aContents; Contributors; Foreword; Preface; 1: General quality planning in the hemostasis laboratory; 2: Hemostasis test validation, performance and reference intervals; 3: International Standards in hemostasis; 4: Sample integrity and preanalytical variables; 5: Internal quality control in the hemostasis laboratory; 6: External quality assessment in hemostasis: its importance and significance; 7: Initial evaluation of hemostasis: reagent and method selection; 8: Point-of-care testing in hemostasis; 9: Assay of factor VIII and other clotting factors 327 $a10: Application of molecular genetics to the investigation of inherited bleeding disorders11: Standardization of D-dimer testing; 12: Diagnostic assessment of platelet function; 13: Laboratory evaluation of von Willebrand disease: phenotypic analysis; 14: Laboratory analysis of von Willebrand disease: molecular analysis; 15: Dilemmas in heritable thrombophilia testing; 16: Evaluation of antiphospholipid antibodies; 17: Monitoring heparin therapy; 18: Monitoring oral anticoagulant therapy; 19: Monitoring new anticoagulants; 20: Detecting and quantifying functional inhibitors in hemostasis 327 $aIndex 330 $a""Over the last decades, major progress has been made in quality assurance of hemostatic laboratory assays. This book will be an indispensable part of every hemostasis laboratory, where, given its hands-on nature, it will rarely sit to get dusty on the shelves.""-Frits R. Rosendaal, Leiden University Medical Center The hemostasis laboratory has a vital role in the diagnosis and management of patients with familial and acquired hemorrhagic and thrombotic disorders. Its role in the monitoring traditional anticoagulant therapy as well as therapy using new anticoagulants presents 606 $aBlood coagulation disorders$xDiagnosis 606 $aBlood$xAnalysis$vLaboratory manuals 606 $aHemostasis 606 $aThrombosis 615 0$aBlood coagulation disorders$xDiagnosis. 615 0$aBlood$xAnalysis 615 0$aHemostasis. 615 0$aThrombosis. 676 $a616.1/57075 700 $aKitchen$b Steve$cDr.$0860323 701 $aOlson$b John David$f1944-$0860324 701 $aPreston$b F. E$0860325 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910782987903321 996 $aQuality in laboratory hemostasis and thrombosis$91919643 997 $aUNINA LEADER 04234nam 22007695 450 001 9910897991303321 005 20250807143333.0 010 $a981-9752-88-4 024 7 $a10.1007/978-981-97-5288-1 035 $a(CKB)36383072200041 035 $a(MiAaPQ)EBC31733692 035 $a(Au-PeEL)EBL31733692 035 $a(DE-He213)978-981-97-5288-1 035 $a(EXLCZ)9936383072200041 100 $a20241019d2024 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNanomedicines for Effective Cancer Therapy /$fedited by Hitoshi Kasai, Hiroshi Uji-i, Johan Hofkens 205 $a1st ed. 2024. 210 1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2024. 215 $a1 online resource (304 pages) 225 1 $aNanomedicine and Nanotoxicology,$x2194-0460 311 08$a981-9752-87-6 320 $aIncludes bibliographical references. 327 $aMost recent designs of nano-prodrugs for Hydroxy camptothecin and Podophyllotoxin -- Pt(II)-diradical complex toward theranostics of cancer -- Design of novel self assembling based drugs -- Innovative gene/nucleic acid delivery system based on optimized intracellular trafficking steps -- Novel targeted therapeutic nano-sized, micro-sized particles as DDS for brain tumor -- Designs of non-toxic and multifunctional nanocarriers for cancer therapy -- Cancer microenvironment-targeted therapy by molecular blocks -- Functional polymer-based siRNA delivery carrier that recognizes site-specific biosignals -- Nanowire-based nanoscopy for intracellular PH sensing -- Bioanalytical nanoprobes and microfluidicis -- Improvement of Multi-photon Microscopy by Utilizing Novel Optical Technologies and Materials -- Intracellular imaging using quantum dots -- Intracellular investigation of prodrug nanoparticles -- Polymeric Nanoparticles for Highly Efficient Multifunctional Drug Delivery Systems -- From 2D to 3D Cancer Cell Models?The Enigmas of Drug Delivery Research -- Control of the Formation Process of Polypeptide Self-assemblies for Understanding Complex Biological Systems: From Nano-physiology to Artificial Cells. 330 $aThis book describes in detail the most up-to-date designs and fabrication techniques for nanomedicines toward effective cancer therapy, while especially emphasizing the biological interaction of nanomedicines at the cellular level, through comprehensive and visual cutting-edge technologies. Unlike other books on the general subject of medicine or drug delivery, this book provides readers the comprehensive information regarding what happens to the nanomedicine at the cell membrane surface, uptake mechanism, and what biochemical process it undergoes inside the cellular matrix. This full overview of the interaction between nanomedicines and cells also provides insights of how to design nanomedicines for effective cancer therapy. . 410 0$aNanomedicine and Nanotoxicology,$x2194-0460 606 $aBiomaterials 606 $aCells 606 $aNanomedicine 606 $aPharmaceutical chemistry 606 $aCancer$xTreatment 606 $aDrug delivery systems 606 $aMaterials$xMicroscopy 606 $aBiomaterials-Cells 606 $aNanomedicine and Nanotoxicology 606 $aMedicinal Chemistry 606 $aCancer Therapy 606 $aDrug Delivery 606 $aMicroscopy 615 0$aBiomaterials. 615 0$aCells. 615 0$aNanomedicine. 615 0$aPharmaceutical chemistry. 615 0$aCancer$xTreatment. 615 0$aDrug delivery systems. 615 0$aMaterials$xMicroscopy. 615 14$aBiomaterials-Cells. 615 24$aNanomedicine and Nanotoxicology. 615 24$aMedicinal Chemistry. 615 24$aCancer Therapy. 615 24$aDrug Delivery. 615 24$aMicroscopy. 676 $a616.99406 702 $aKasai$b Hitoshi 702 $aUji-i$b Hiroshi 702 $aHofkens$b Johan 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910897991303321 996 $aNanomedicines for Effective Cancer Therapy$94430172 997 $aUNINA